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Summary.-A study was made ofthe levels of ribonuclease (RNase) in human serum,
using 2 independently collected banks of samples from Scripps Clinic and Research
Foundation and the Mayo Clinic, each bank representing more than 100 individuals.
These serum samples originatedfrom across-sectionofnormalindividuals, smokers,
patients with benign tumours, and patients with a variety of neoplasms. Elevated
levels of serum RNaseoccurredin68o ofthesamplesfromindividualswithmalignant
disease. Elevated levels also occurred in 24%o of the samples from individuals with
benign tumours and in38°, of the smoker controls from the Mayo Clinic serum bank.
Using ion-exchange chromatography, pooled sera from normal individuals and
cancer patients were fractionated by differential salt elution. Each pool showed 2
distinct peaks of RNase activity, and both peaks were elevated to the same degree in
the cancer serum pools. Similar results were obtained after thin-layer-gel isoelectric
focusing ofboth normal and cancer sera; no new species of RNase could be detected in
the sera of patients with malignant diseases. The results suggested a generalized
nonspecific increase in serum RNase in these patients.
THERE HAS BEEN increasing interest in
recent years in the examination of serum
factors which could provide a sensitive and
reliable means of monitoring the presence
or progression of neoplasms in humans.
Numerous reports have appeared in which
significant increases in the level of ribo-
nuclease (RNase) were observed in the
sera of cancer patients. Zytko and Cantero
(1962) reported that 600% of patients with
malignant diseases demonstrated serum
RNase levels that were significantly higher
than those of normal individuals. Chretien
et al. (1973) suggested a relationship
between serum RNase levels and tumour
histology, finding that sera from
individuals with adenocarcinomas and
squamous carcinomas yielded elevated
activities, while those from sera ofpatients
with sarcomas and melanomas were not
significantly different from normal values.
Catalona et al. (1973) observed increased
RNase levels in a majority ofthe sera from
patients with various urological cancers.
Drake et al. (1975) also reported significant
increases in serum RNase levels of the
majority of cancer patients, using an assay
system which incorporated a variety of
specific polynucleotide substrates instead
of native RNA. A report by Reddi and
Holland (1976) also indicated the effective-
ness of serum RNase as an indicator of
malignancy in general, but most notably
in the case of pancreatic carcinoma. Most
recently, Sheid et al. (1977) have suggested
that the serum RNase level is a reliable
tumour marker in the detection of an
ovarian malignancy.
The present study was undertaken to
examine further the reliability of serum
RNase measurement as an aid to the
diagnosis of human cancer. Sera from
normal individuals and those with various
malignant diseases or benign tumours have
been examined for total RNase activity
by means of a sensitive assay system using
radiolabelled substrate. We have also
fractionated sera from normal individualsSERUM RNASE ACTIVITY IN CANCER PATIENTS
and cancer patients to determine whether
new species of RNase are distinguishable
in the sera of individuals with malignant
disease.
MATERIALS AND METHODS
Sera.-Two sources of serum samples were
used throughout this study. The first group
was from patients at Scripps Clinic and Re-
search Foundation, and the second from the
National Cancer Institute Mayo Clinic Serum
Bank, as a generous gift from Dr Ronald
Herberman. The latter group included serum
from normal controls and cancer patients, as
well as smoker controls and individuals w%Nith
benign tumours. Cancer sera included samples
of carcinoma, lymphoma, melanoma, leu-
kaemia, Hodgkin's disease and various un-
related malignant diseases. Frozen samples
were thawed once on the day of use, and the
appropriate dilutions were made in cold
10mm Tris-HCi buffer, pH 7 4. Aliquots ofthe
diluted serum were added directlv to reaction
mixtures for assay of RNase activity.
lodination of R1NA. Partially purified
ribosomal RNA wN,as prepared from cells of
Escherichia coli (100 g wiet wt) according to
the phenol-extraction method ofKirby (1956).
The final RNA preparation was found to
contain less than 500 DNA as contaminant.
lodination of this RNA using 1251 (New
England Nuclear) was performed as described
by Commerford (1971). The reaction mixture
contained 0-1 ml of 1-25 mm KI (equilibrated
with 200 ,uCi 1251), 0.1 of 7.5 mM TICI,
0 3 ml of 0-1 M acetate buffer, pH 5 0, and
250 j,g RNA. The mixture was heated for
15 min at 60°C, chilled in ice, and 25 jul of
01M Na2SO3 and 0-1 ml of IM ammonium
acetate: 0 5m ammonium hydroxide were
added. The system was heated for 20 min at
60°C and then chilled in ice. Labelled RNA
wias separated from unreacted 1251 by passage
over a column of Sephadex G-50 fine using
0-1M ammonium acetate as eluent. The
fractions containing labelled RNA were
pooled and stored at -20°C for use in the
assay. The final sp. act. was 0-1 [Ci/jug. R.XVase assay. The reaction mixture used
for assay of serum RNase activity consisted
of: 0-1 ml of IM Tris-HCl buffer, pH 7-4;
0-1 jug of 1251-RNA (104 ct/min); diluted
serum sample (25-100 pi) and distilled water
to a final volume of 1-0 ml. Reaction blanks
containing the above components but with
distilled water in place of serum sample were
included for each set of sera assayed.
The reaction was initiated by incubating
tubes at 37°C. After 5 min the reaCtion was
terminated by adding 0-1 ml (500 ,ug) of un-
labelled carrier RNA (Sigma Chemical Co.,
St Louis, Mo.), followed immediately by
1-0 ml of "N perchloric acid at 4°C. The tubes
were then mixed and allowed tostandinicefor
10 min. The precipitated RNA was removed
by centrifugation and a sample of the super-
natant was withdrawn and counted. Acid-
soluble radioactivity was determined using a
Packard Auto-Gamma Scintillation spectro-
meter. One unit of activity is defined as the
release of 1 nmol of nucleotide tinder the
conditions of the assay.
Column chromatography.-Samplesofserum
from normal or cancer pools w%Aere chromato-
graphed on DEAE-cellulose (DE-52, Wthat-
man) columns (1-5 x 12 cm). The respective
samples (0-5 ml) were washed on to the
columns wNith 50 ml of 20mM potassium
phosphate buffer, pH 6-8, containing 1mm
ethylenediaminetetraacetic acid, 1mM fi-
mercaptoethanol and 01mM phenylmethyl-
sulphonylfluoride. Material retained by the
columns was eluted using 50 ml of the same
buffer containing 300mM KCI. Fractions of
5*0 ml were collected, and fractions contain-
ing material eluting from the column with
low salt or high salt were pooled and assayed
for RNase activity as described.
Thin-layer-gel isoelectric focusing. Samples
ofnormal and cancersera (5 1ul) weresubjected
to isoelectric focusing in a pH 3*5-10 gradient
in Sephadex G-75 superfine (Pharmacia)
using a Desage/Brinkmann thin-layer electro-
phoresis apparatus equipped wNith cooling
block. Gel layers were prepared according to
the manufacturer's directions on glass plates
(10 x 20 cm) and prefocused for 4 h at 200 V
and 4°C. The anodic solution was 0-2N
sulphuric acid, and the cathodic solution was
0 4N eth- lenediamine. Samples were applied
as bands using the edges of glass coverslips,
and isoelectric focusing was carried out for
4 h at 500 V. The focused gel was fractionated
by scraping 1 cm zones, and the samples were
eluted overnight in 100mM Tris-HCl buffer,
pH 7-4, at 4°C. Samples of eluate from each
fraction were assayed for RNase activity as
described above. Similar gel samples from
zones without addled protein were placed in
1 0 ml of distilled water and measurements
were obtairned to determine the pH gradient.
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RESULTS
RlNase assay
A sensitive, radiolabel assay was
developed, requiring only 100 ng of RNA
substrate per assay. The substrate of
choice was purified ribosomal RNA from
the bacterium E. coli. This provided a
native RNA substratewithrandomnucleo-
tide sequences, obviating the need for a
variety of synthetic polynucleotides as
substrates. The selected RNA, however,
had a cytidine content similar to that of
the yeast RNA used by Schmukler et al.
(1975) to demonstrate the preferential
hydrolysis of cytidylic acid residues by
plasma RNase. The assay is designed in
termsofsimplicityfortheclinicallaboratory
to measure any generalized increase in
serum RNaselevels without differentiating
individual RNase species or specificities.
Previously described procedures have
relied upon optical-density measure-
ments ofacid-soluble material, and as such
have been greatly limited in sensitivity and
accuracy. The present assay can easily
measure ng levels of serum RNase. By
increasing the degree of radiolabelling of
the substrate, the effective sensitivity can
be extended into the pg range. Such an
assay would have the advantages of
accurate quantitation of activity, minimal
sample size and minimal incubation time.
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Preliminaryexperimentswereperformed
to establish the appropriate serum dilu-
tions for proportional release of radiolabel
into an acid-soluble form. Fig. 1 demon-
strates the results of such experiments
using normal human serum. Release of
radioactivity was found to be linear with
time and proportional to enzyme con-
centration, in serum dilutions over the
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FIG. 1. Activity vs concentration plot of
RNase from normal serum. Dilutions of
serum over the range 1/200 to 1/500 were
assayed as described in Materials and
Methods. Results are expressed as units of
RNase at the respective serum dilution.
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Disease Malignant
Diseases
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FIG. 2.-Levels of RNase detected in normal
and cancer sera. Results are expressed as
units of RNase/ml of serum. Dashed line
represents abnormal level for each group,
defined as normal mean plus two standard
(leviations. (A), Samples from Scripps Clinic
andl Research Foundation; (B), Samples
from National Cancer Institute Mayo Clinic
Serum Bank.
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range 1/200 to 1/500. Assay of less dilute
and undiluted serum produced non-linear
release of counts into an acid-soluble form,
under the described conditions of assay.
All subsequent assays of serum RNase
activity were performed within this dilu-
tion range.
RNase levels in serum
Using the above assay, 2 collections of
serum samples, one from Scripps Clinic
and Research Foundation and one from
the Mayo Clinic Serum Bank, were tested
for levels of RNase. The results of these
experiments are shown graphically in Fig.
2 and summarized in Table I. Samples of
normal sera from Scripps Clinic yielded a
mean RNase value of 266 u/ml, and the
comparable value of273 u/mlwasobtained
from the Mayo Clinic samples. The results
with the normal sera emphasize the
reliability of the assay system. Two
TABLE 1. Statistical analysis of RNase activities in control and cancer sera.
(A) Scripps Clinic and Research Foundation
Range Mean
pIe No. (u/mi) units/ml s.d.
15 192-355 266 39
13 187-509 376 85
isease 9 328-622 437 84
14 297-554 417 84
47 261-545 414 67
aant
5 392-574
0*
<0-01
<0-01
<0-01
<0-01
466 69 <0 01
(B) National Cancer Institute Mayo Clinic Serum Bank
Normal
Smoker
Benign tumours
Melanoma
Carcinoma
21
21
29
10
76
137-426
230-946
208-804
287-774
196-765
273
398
376
413
430
66
165
149
140
117
<0-01
<0-01
<0-01
<0-01
* From Students' t test.
t Reticulum-cell sarcoma (455); ihabdiosarcoma (392); melanoma (574); multiple
myeloma (425); cold-agglutinin (lisease with thrombocytopenia (485).
TABLE II. o% of test samples with raised RNase activity
(A) Scripps Clinic and Research Foundation
Sample No. No. raised % raised
Normal 15 1 7
Leukaemia 13 8 62
Hodgkin's disease 9 8 89
Lymphoma 14 11 79
Carcinoma 47 40 85
Other malignant
diseases 5 5 100
(B) National Cancer
Normals
Smokers
Benign tumours
Melanoma
Carcinoma
Breast
Lung
Lower G.I.
Upper G.I.
Pancreas
Institute Mayo Clinic Serum Bank
21 1 5
21 8 38
29 7 24
10 6 60
76 40 53
20 10 50
27 10 37
20 13 65
6 5 83
.3 2 67
Sami
Normal
Leukaemia
Hodgkin's di
Lymphoma
Carcinoma
Other maligr
diseasest
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independently collected and assayed pools
of samples gave comparable values for the
mean normal level of serum RNase.
As shown in Table I, the mean serum
RNase levels for all of the different types
of malignant diseases studied were signifi-
cantly elevated when compared with the
mean values of normal sera (P<001 for
all comparisons). Table II summarizes the
results of all RNase assays performed for
each group of sera when compared with
the respective normal controls. An ab-
normal RNase level is defined as greater
than the normal mean plus 2 standard
deviations. With respect to the sera of
cancer patients from Scripps Clinic, the
percentage of samples with abnormal
enzyme levels ranged from 62%0 for
leukaemias to 89% for Hodgkin's disease
(Table IIA). The carcinoma samples re-
presented 10 different primary sites, but
the majority ofthe samples (24) were from
individuals with breast carcinomas. In the
latter case, elevated RNaselevels were 83%0
of the serum samples tested. Abnormal
values of RNase were found in 5300 and
60,0o respectively, of the sera from indi-
viduals with carcinomas and melanomas
from the National Cancer Institute Mayo
Clinic Serum Bank (Table IIB). When the
carcinomas were classified as to primary
site of origin, the incidence of elevated
RNase level was lowest for the lung
carcinomas.
However, of equal interest in these
assays were the results of tests on indi-
viduals with various nonmalignant con-
ditions. The mean serum RNase values
from smokers and individuals with benign
tumours were found to be significantly
elevated when compared with normal con-
trols, as evidenced by the results from the
Mayo Clinic Serum Bank. Abnormal levels
of serum RNase were found in 38%0 of the
smokers and 24% of the individuals with
benign tumours.
Fractionation of serum R.Nase
The increased levels of RNase seen in
the sera ofa majority ofthe cancer patients
could represent a general raising ofnormal
serum RNase, or might result from the
presence of a new species of RNase. In the
latter case, the proportional elevation of a
new activity could be several magnitudes
higher than the total increase observed. In
order to test this possibility, pools of
normal sera and cancer sera showing large
increases in activity were subjected to
chromatography on DEAE-cellulose. Such
experiments, in which both serum pools
were fractionated on DEAE-cellulose
columns, using stepwise elution with in-
creasing salt concentration (50-300mM
KCI), revealed 2 separable RNase
activities for both sera. The first activity
appeared in fractions representing material
that did not adsorb on to the column, while
a second activity eluted in the high-salt
fractions. No additional species of RNase
were detected in the pooled cancer sera.
Parallel experiments, using the pooled
normal or cancer sera, were then carried
out to quantitate the level of RNase in
each fraction. Table III shows the results
TABLE III. RNaise activity in DEAE-
cellulose fractions of normal and cancer
serum pools
Serum
pools
Normal
Cancer
Cancer
Normal
DEAE-cellulose fraction
Non-adsorbed Adsorbed
100 400
250 1000
2-5 2 5
Values are expressed in terms of units of the com-
bined low- or high-salt fractions from DEAE-cellu-
lose columns.
of RNase assays performed with the com-
bined fractions oftheunadsorbed andhigh-
salt eluates for each serum pool. For both
the normal and cancer sera, protein
fractionation by ion-exchange chroma-
tography appears to amplify the RNase
activity, perhaps by separating out one or
more nuclease inhibitors. Moreover, for
both the unadsorbed and adsorbed pools,
the levels of the cancer-serum activities
were substantially greater than the corres-
ponding normal values. The ratio of these
activities was constant for each pool,
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FIG. 3.-Fractionation of RNase activity of
normal and cancer sera by thin-layer-gel
isoelectric focusing. Results are expressed as
units of RNase in the respective fractions.
(0), Normal serum; (D), Cancer serum;
(0), pH
suggesting a nonspecific increase in total
serum enzyme activity in the cancer
patient.
Similar results were obtained with
serum samples subjected to iso-electric
focusing in thin-layer gels (Fig. 3). Two
peaks ofactivity for each sample resulted;
activity in each ofthe cancer-serum peaks
was increased to the same over the corres-
ponding normal-serum peak. No new
activities could be demonstrated in the
pooled cancer sera.
DISCUSSION
Drake et al. (1975) have suggested that
the usefulness of serum RNase measure-
ment as a test for malignant disease
depends upon assay of activity with a
variety of polynucleotide substrates, in-
cluding poly C, poly U or poly A.poly U.
Whereas 6/26 patients with non-Hodgkin's
lymphoma exhibited elevated activity
against poly A.poly U, 18 of the same
patients demonstrated raised activity
against poly C where used as substrate.
Similar results of differentially raised
RNase activity were obtained from sera of
other malignant diseases, and led the
authors to question the use of only native
RNA as substrate in this assay. Our use
of native RNA with random nucleotide
sequences as substrate has provided results
which are comparable with those reported
by Drake et al. (1975). Because of the
limited range of linearity and proportion-
alityobtainedinRNasemeasurements, itis
possible that earlier studies which reported
normal serum enzyme levels in cancer
patients have suffered from inadequate
definition of the assay system itself.
Fractionation ofnormal sera on DEAE-
cellulose columns resolved serum RNase
activity into 2 distinct fractions: one that
is not adsorbed to the column and the
other which adsorbs and is eluted by high
salt concentrations. Pooled sera from
cancer patients with raised levels gave an
identical elution profile, but the RNase
activities were observed to be similarly
increased in both fractions. Isoelectric
focusing of normal and cancer-serum
samples detected 2 major peaks of RNase
activity for each serum type. The major
peak in each sample corresponded to an
approximate isoelectric point of 70-
7'6. An isoelectric point of 5'6 was
obtained for the second activity of each
serum type. Both peaks of cancer-serum
activity were raised to nearly the same
extent over the corresponding activity of
the normal serum peaks. By these criteria,
the increased level ofRNase in cancer sera
appears to be due to a generalized increase
in total serum RNase activity and not to
the synthesis of any unique species. It is
possible, however, that additional studies
to further resolve the activities demon-
strated here could reveal new or unique
RNases in the sera ofpatients with malig-
nant disease (Blank and Dekker, 1977).
The results of the present study agree
with those ofother investigators who have
reported increases in the level of serum
RNase in cancer patients (Zytko and
Cantero, 1962; Chretien et al., 1973;
Catalona et al., 1973; Drake et al., 1975;
Reddi and Holland, 1976; Sheid et al.,
1977). For the samples from Scripps
Clinic, the percentage of abnormal sera in
individual cancers ranged from 62% for
leukaemias to 89% for Hodgkin's disease.
It hasbeenreportedthatrenalinsufficiency
produces raised levels of serum RNase
(Reddi and Holland, 1976; Karpetsky et
al., 1977). Relevant data were available
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for 16 of the patients from Scripps Clinic
who had abnormal RNase levels. Of these
patients, 15 showed no evidence of renal
insufficiency as indicated by normal BUN
values or creatinine levels on the day on
which the serum sample was taken. Ab-
normal levels in cancer sera from the
National Cancer Institute occurred in 53%
of the samples from carcinoma patients
and 60% of the samples from melanoma
patients. Despite the fact that no attempt
was made to discern the status of each
patient in terms of disease progression, we
have found that 68% of all cancer sera
tested could be classified as abnormal. This
result suggested an excellent correlation
between the appearance of abnormal
RNase levels in serum and the presence of
neoplastic disease. Furthermore, the ele-
vated values were observed in a variety of
different malignant disorders and were not
limited to one particular type.
This study also demonstrated that ab-
normal RNase levels can be measured in a
significant proportion of 2 groups of
individuals without malignant disease,
namely those with benign tumours (24%)
and smokers (38%). The reason for such
levels in these groups is not immediately
obvious, and deserves further study. If
raised RNase activity in such individuals
could indicate a predisposition to malig-
nant disease, the potential for the use of
this assay may attain greater significance.
But until such a correlation is demon-
strated, the data must be interpreted as
imposing a strong limitation on the use of
serum RNase alone as a tumour marker.
Itsefficacy might bebestusedbyincluding
it as part of a panel of tumour markers.
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